Clinical Trial Update: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 safety trial update for SEA-CD70 in myeloid malignancies; the study in myelodysplastic syndrome and acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• SEA-CD70 (SEA-CD70)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING